Biogen hits snag after Alzheimer’s drug fails to win support from FDA panel – CNBC

A Food and Drug Administration panel on Friday unexpectedly declined to endorse Biogen’s experimental Alzheimer’s drug aducanumab in a setback for the pharmaceutical company.
In an 8-1 vote, the pan… [read more]

Leave a Reply